Skip to main content

Multi-platform 'Omics Analysis to Determine TB Vaccine Correlates


EMSL Project ID
51809

Abstract

In recent years, mass spectrometry-based integrated multi-omics analyses have allowed for powerful interrogations of patient samples, and the identification of correlates of risk for tuberculosis disease progression and various viral infections including Ebola virus disease outcomes. The overarching goal of this study is to identify multimolecular biosignatures elicited by M72/AS01E vaccination correlating to protection from active TB. In this pilot study, our primary aim is to examine the lipidomic, metabolomic, and proteomic profiles of plasma collected from M72/AS01E vaccine trial enrollees (TB-018 trial) to identify vaccine-elicited effects that may serve as reproducible and robust correlates of protection. Our secondary aim is to integrate these data with complementary datasets such as transcriptomics to identify biological signatures of vaccine-induced response. This effort represents the continuation of an ongoing productive lipidomics-pathogenesis collaboration (ref. 1) between the Tafesse group at Oregon Health & Science University (OHSU) and the Integrative Omics group at Pacific Northwest National Laboratory (PNNL) and takes advantage of the existing partnership between the two institutions.

Project Details

Start Date
2021-02-10
End Date
2021-09-30
Status
Closed

Team

Principal Investigator

Jennifer Kyle
Institution
Pacific Northwest National Laboratory

Team Members

Bobbie-Jo Webb-Robertson
Institution
Pacific Northwest National Laboratory

Thomas Metz
Institution
Pacific Northwest National Laboratory